Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
A phase 3 trial testing ADI-PEG20 in hepatocellular carcinoma, now recruiting.
Overview
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT05317819, led by Polaris, and recruiting when checked on 2026-09-11. Official title: A Randomised, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma. Planned enrolment is 300 participants (estimated). The study started in 2022-03-14 and primary completion is expected in 2028-09. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment
Shares Hepatocellular carcinoma and the tag ctgov-ingest.
- TrialA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Shares Hepatocellular carcinoma and the tag ctgov-ingest.
- TreatmentAZD9793
Shares Hepatocellular carcinoma and the tag ctgov-ingest.
- TreatmentADG126
Shares Hepatocellular carcinoma and the tag ctgov-ingest.
- TreatmentIBI310
Shares Hepatocellular carcinoma and the tag ctgov-ingest.
- TreatmentBudigalimab
Shares Hepatocellular carcinoma and the tag ctgov-ingest.
- TreatmentLivmoniplimab
Shares Hepatocellular carcinoma and the tag ctgov-ingest.
- TreatmentCobolimab
Shares Hepatocellular carcinoma and the tag ctgov-ingest.